Today Philip Morris International reiterated its support for the World Health Organization's (WHO) efforts to create a Framework Convention on Tobacco Control Framework (FCTC).
David Davies, Senior Vice President of Philip Morris International, stated: "We think the WHO has a legitimate role in proposing strong and effective regulations on the marketing, manufacturing and sale of tobacco products, especially with the goal to prevent minors from smoking."
The company confirmed that in the past the consultancy firm Mongoven Biscoe and Duchin had provided information about the process and progress of WHO's Framework Convention on Tobacco Control. David Davies said that "it is nothing out of the ordinary to seek information and understand the processes so that the company can make a constructive contribution." The company no longer has a relationship with this consultancy firm.
Philip Morris International has been very clear and open about its position on the FCTC. The company supports the WHO's FCTC based on four key principles:
smoking-related decisions should be made on the basis of consistent public health messages
effective measures should be taken to prevent minors from smoking
the ability of adults to choose to smoke
all manufacturers of tobacco products should compete on a level playing field.
Philip Morris International also reiterated its desire to work with the WHO and member States. Although WHO and others have called for the exclusion of tobacco companies from the FCTC process, Philip Morris believes that all interested parties, including tobacco companies, have a legitimate role to play.
PMI is the world’s leading international tobacco company, with six ot the world’s top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the developement and commercialization of Reduced-Risk Products (RRPs). RRPs is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. Through multidisciplinary capabalities in product development, state-of-the-art facilities, and indusrty-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements.